О клинике
Назад
О клинике О нас Хадасса в цифрах История Фототур Схема территории Новости События
Отделения
Назад
Аллергология и иммунология Гастроэнтерология Гематология Генетика Гинекология Дерматология Инфекционные заболевания Кардиология Неврология Нейрохирургия Нефрология Онкология Ортопедия Отоларингология Офтальмология Педиатрия Пластическая хирургия Психиатрия Пульмонология Радиология Радиотерапия Реабилитология Сосудистая хирургия Стоматология Торакальная хирургия Урология Хирургия Челюстно-лицевая хирургия Эндокринология Ядерная медицина Редкие заболевания Трансплантация костного мозга
Врачи
Пациентам
Назад
Отзывы и истории успеха Медицинские брошюры Пошаговое руководство Болезни от А до Я Процедуры и услуги от А до Я Прейскурант лекарств
Специалистам
Назад
Стажировки
Контакты
info@hds.org.il +9722 560-9534
О клинике
Назад
О клинике О нас Хадасса в цифрах История Фототур Схема территории Новости События
Отделения
Назад
Аллергология и иммунология Гастроэнтерология Гематология Генетика Гинекология Дерматология Инфекционные заболевания Кардиология Неврология Нейрохирургия Нефрология Онкология Ортопедия Отоларингология Офтальмология Педиатрия Пластическая хирургия Психиатрия Пульмонология Радиология Радиотерапия Реабилитология Сосудистая хирургия Стоматология Торакальная хирургия Урология Хирургия Челюстно-лицевая хирургия Эндокринология Ядерная медицина Редкие заболевания Трансплантация костного мозга
Врачи
Пациентам
Назад
Отзывы и истории успеха Медицинские брошюры Пошаговое руководство Болезни от А до Я Процедуры и услуги от А до Я Прейскурант лекарств
Специалистам
Назад
Стажировки
Контакты
info@hds.org.il +9722 560-9534

Дина Бен-Иехуда

Отделение: Гематология
Должность: Гематолог
Языки: Английский, Иврит
Принимает: только взрослых
Написать в WhatsApp Записаться на прием

Профессор Дина Бен-Иехуда

Образование

Родилась в Хайфе, в 1953 г. Выпускница медицинского факультета университета им. Бен-Гуриона.

Специализация

Научные интересы: молекулярная биология гематологических новообразований эпидемиология генная терапия.

Профессиональная деятельность

Руководит отделением гематологии университетской клиники “Хадасса” с апреля 2000 года.

Научные публикации

AI-BASED HEALTH AND BIOLOGICAL SCIENCES: AN OPPORTUNITY FOR ISRAELI LEADERSHIP
Challenges in Implementing Guideline on Integrative Oncology and Pain: The Israeli Perspective
Risk factors and outcomes of COVID-19 in adult patients with hematological malignancies: A single-center study showing lower than expected rates of hospitalization and mortality
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
From skepticism to openness: a qualitative narrative analysis of medical students' attitudes following an integrative medicine course
From the "what" to the "how": Teaching integrative medicine-related skills to medical students during COVID-19
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial
Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma
Parameters associated with sperm quality prior to chemotherapy in lymphoma patients
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
THE TIME HAS COME! COMPLEMENTARY MEDICINE IN MEDICAL TRAINING IN ISRAEL
Evaluation of cerebrospinal clonal gene rearrangement in newly diagnosed non-Hodgkin's lymphoma patients
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
American Funding Cutback to East Jerusalem Hospitals: A Blow to the Health of the City
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
Serum organochlorines and non-Hodgkin lymphoma: A case-control study in Israeli Jews and Palestinians
The oncogenic fusion protein CBFB-SMMHC downregulates CD48 to evade NK cell recognition
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
Presence of autoimmune disease affects not only risk but also survival in patients with B-cell non-Hodgkin lymphoma
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients
Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia
Ethnic variation in medical and lifestyle risk factors for B cell non-Hodgkin lymphoma: A case-control study among Israelis and Palestinians
The JAK2V617F mutation in normal individuals takes place in differentiating cells
The prognostic value of bone marrow involvement at the molecular level in aggressive lymphoma
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
Hypersensitivity reactions to rituximab: 53 successful desensitizations in 7 patients with severe, near-fatal reactions
Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
Associations between B-cell non-Hodgkin lymphoma and exposure, persistence and immune response to hepatitis B
Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy
Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma
Autologous transplantation and maintenance therapy in multiple myeloma
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
Показать ещё 42 статьи Скрыть статьи
Заболевания
Болезнь Кастлемана
Процедуры
Трансплантация костного мозга
Остались вопросы?
Напишите нам и мы свяжемся с вами в течение ближайшего времени и ответим на все интересующие вопросы